Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10724
Title: Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Austin Authors: Wong, Peter;Lawrentschuk, Nathan;Bolton, Damien M 
Affiliation: University of Melbourne, Department of Surgery, Austin Hospital, Melbourne, Australia
Issue Date: 1-Jan-2009
Publication information: Current Opinion in Urology; 19(1): 7-12
Abstract: Phosphodiesterase 5 (PDE-5) inhibitors are established as first-line therapy in erectile dysfunction. There is emerging evidence that they may have a role in treating patients with lower urinary tract symptoms (LUTS) from benign prostatic hypertrophy.All three commonly used PDE-5 inhibitors (sildenafil, vardenafil and tadalafil) appear to improve LUTS as measured by the International Prostate Symptom Score. However, to date, no change in urinary flow rates have been demonstrated.Erectile dysfunction and LUTS frequently coexist in men of advancing age. There appears to be an emerging role for PDE-5 inhibitors as a treatment for both conditions. Further studies are required to elicit the exact mechanism of action in LUTS.
Gov't Doc #: 19057210
URI: http://ahro.austin.org.au/austinjspui/handle/1/10724
DOI: 10.1097/MOU.0b013e328316c357
URL: https://pubmed.ncbi.nlm.nih.gov/19057210
Type: Journal Article
Subjects: 5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists.therapeutic use
Erectile Dysfunction.drug therapy.physiopathology
Humans
Male
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors.therapeutic use
Prostatic Hyperplasia.drug therapy.physiopathology
Urinary Tract.physiopathology
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.